Abatacept subcutaneous + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Polymyositis
Conditions
Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy, Overlap Myositis, Juvenile Myositis Above the Age of 18
Trial Timeline
May 4, 2017 → Aug 2, 2022
NCT ID
NCT02971683About Abatacept subcutaneous + Placebo
Abatacept subcutaneous + Placebo is a phase 3 stage product being developed by Bristol Myers Squibb for Polymyositis. The current trial status is completed. This product is registered under clinical trial identifier NCT02971683. Target conditions include Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy.
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02971683 | Phase 3 | Completed |
Competing Products
6 competing products in Polymyositis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tacrolimus | Astellas Pharma | Pre-clinical | 26 |
| Placebo + BAF312 | Novartis | Phase 2 | 27 |
| BAF312 + Placebo | Novartis | Phase 2 | 27 |
| MEDI7734 + Placebo | Amgen | Phase 1 | 29 |
| KZR-616 | Kezar Life Sciences | Phase 2 | 25 |
| KZR-616 + Placebo | Kezar Life Sciences | Phase 2 | 25 |